Quasi 4D-QSAR and 3D-QSAR study of the pan class i phosphoinositide-3- kinase (PI3K) inhibitors

Medicinal Chemistry Research

Volumn 22, Issue 4, 2013, Pages 1587-1596

  Safavi Sohi, Reihaneh ^a   Ghasemi, Jahan B ^a  

^a K N TOOSI UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

4D QSAR; CoMFA; Molecular dynamic simulation; Phosphoinositide 3 kinase (PI3K) inhibitors

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

ARTICLE; BIOLOGICAL ACTIVITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; INHIBITION KINETICS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PREDICTIVE VALUE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84879693271     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0151-6     Document Type: Article

References (41)

1. Andrade CH, Pasqualoto KFM, Ferreira EI, Hopfinger AJ (2010) 4D-QSAR: perspectives in drug design. Molecules 15:3281-3294
2. Berendsen HJC, Postma JPM, Van Gunsteren WF, DiNola A, Haak J (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81:3684
3. Bhonsle JB, Wang Z, Tamamura H, Fujii N, Peiper SC, Trent JO (2005) A simple, automated quasi-4D-QSAR, quasi-multi way PLS approach to develop highly predictive QSAR models for highly flexible CXCR4 inhibitor Cyclic Pentapeptide Ligands Using Scripted Common Molecular Modeling Tools. QSAR Comb Sci 24:620-630
4. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655
5. Clark M, Cramer RD III, Van Opdenbosch N (1989) Validation of the general purpose Tripos 5.2 force field. J Comput Chem 10:982-1012
6. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075
7. Cramer RD III, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967
8. Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N log (N) method for Ewald sums in large systems. J Chem Phys 98:10089-10092
9. Dimitrov S, Dimitrova G, Pavlov T, Dimitrova N, Patlewicz G, Niemela J, Mekenyan O (2005) A stepwise approach for defining the applicability domain of SAR and QSAR models. J Chem Inf Model 45:839-849
10. Doucet JP, Panaye A (2009) Three dimensional QSAR: applications in pharmacology & toxicology (QSAR in environmental & health sciences). CRC Press, New York
11. Doweyko AM (2004) 3D-QSAR illusions. J Comput Aided Mol Des 18:587-596
12. Dragos H, Gilles M, Alexandre V (2009) Predicting the predictability: a unified approach to the applicability domain problem of QSAR models. J Chem Inf Model 49:1762-1776
13. Frédérick R, Denny WA (2008) Phosphoinositide-3-kinases (PI3 Ks): combined comparative modeling and 3D-QSAR to rationalize the inhibition of p110α. J Chem Inf Model 48:629-638
14. Fruman DA, Bismuth G (2009) Fine tuning the immune response with PI3 K. Immunol Rev 228:253-272
15. Ghasemi JB, Safavi-Sohi R (2011) 4D-LQTA-QSAR and docking study on potent gram-negative specific LpxC inhibitors: a comparison to CoMFA modeling. Mol Divers. doi: 10.1007/s11030-011-9340-3
16. Ghasemi JB, Salahinejad M, Rofouei MK (2011) Review of the quantitative structure-activity relationship modelling methods on estimation of formation constants of macrocyclic compounds with different guest molecules. Supramol Chem 23:615-631. doi: 10.1080/10610278.2011.581281
17. Golbraikh A, Tropsha A (2002a) Beware of q2! J Mol Graph Model 20:269-276
18. Golbraikh A, Tropsha A (2002b) Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comput Aided Mol Des 16:357-369
19. Hopfinger A, Wang S, Tokarski JS, Jin B, Albuquerque M, Madhav PJ, Duraiswami C (1997) Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J Am Chem Soc 119:10509-10524
20. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM (2007) The structure of a human p110a/p85a complex elucidates the effects of oncogenic PI3Ka mutations. Science 318:1744-1747
21. Itai A, Tomioka N (1993) In: Kubinyi H (ed) 3D QSAR in drug design: theory, methods and applications, vol 1. Kluwer Academic Publishers, Leiden, pp 200-206
22. Jiang BH, Liu LZ (2008) PI3 K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta, Proteins Proteomics 1784:150-158
23. Kennard RW, Stone LA (1969) Computer aided design of experiments. Technometrics 11:137-148
24. Kiralj R, Ferreira MMC (2009) Basic validation procedures for regression models in QSAR and QSPR studies: theory and application. J Braz Chem Soc 20:770-787
25. Kong D, Yamori T (2008) Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci 99:1734-1740
26. Kusalik PG, Svishchev IM (1994) The spatial structure in liquid water. Science 265:1219
27. Maira SM, Stauffer F, Schnell C, García-Echeverría C (2009) PI3 K inhibitors for cancer treatment: where do we stand. Biochem Soc Trans 37:265-272
28. Martins JPA, Barbosa EG, Pasqualoto KFM, Ferreira MMC (2009) LQTA-QSAR: a new 4D-QSAR methodology. J Chem Inf Model 49:1428-1436
29. Matthews DJ, Gerritsen ME (2010) Targeting protein kinases for cancer therapy, Intracellular signal transduction cascades, Targeting protein kinases for cancer therapy. Wiley, Hoboken, pp 266-270
30. Parrinello M, Rahman A (1980) Crystal structure and pair potentials: A molecular-dynamics study. Phys Rev Lett 45:1196-1199
31. Rewcastle GW, Denny WA (2009) Inhibitors of phosphatidylinositol 3-kinases: the next wave of anti-cancer drugs? Chem New Zeal 73:9-11
32. Rewcastle GW, Gamage SA, Flanagan JU, Frederick R, Denny WA, Baguley BC, Kestell P, Singh R, Kendall JD, Marshall ES (2011) Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3 K) inhibitor 2-(difluoromethyl)-1-[4,6-di (4-morpholinyl)-1,3,5-triazin-2- yl]-1H-benzimidazole (ZSTK474). J Med Chem 54:7105-7126. doi: 10.1021/jm200688y
33. Ricketts EM, Bradshaw J, Hann M, Hayes F, Tanna N, Ricketts DM (1993) Comparison of conformations of small molecule structures from the Protein Data Bank with those generated by Concord, Cobra, ChemDBS-3D, and Converter and those extracted from the Cambridge Structural Database. J Chem Inf Model 33:905-925
34. Rusinko A III, Sheridan RP, Nilakantan R, Haraki KS, Bauman N, Venkataraghavan R (1989) Using CONCORD to construct a large database of three-dimensional coordinates from connection tables. J Chem Inf Model 29:251-255
35. Santos-Filho OA, Hopfinger AJ (2002) The 4D-QSAR Paradigm: Application to a Novel Set of Non-peptidic HIV Protease Inhibitors. Quant Struc Act Rel 21:369-381
36. Shim J, MacKerell AD Jr (2011) Computational ligand-based rational design: role of conformational sampling and force fields in model development. Med Chem Commun 2:356-370
37. Tropsha A, Gramatica P, Gombar VK (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 22:69-77
38. Verma J, Khedkar VM, Coutinho EC (2010) 3D-QSAR in drug design-A review. Curr Top Med Chem 10:95-115
39. Wang R, Gao Y, Liu L, Lai L (1998) All-orientation search and all-placement search in comparative molecular field analysis. J Mol Model 4:276-283
40. Ward SG, Finan P (2003) Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 3:426-434
41. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P (2003) Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 10:207-213